Testing a new immunotherapy drug for advanced lung cancer

Plain-English translation of NCT07362459 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a new immunotherapy drug called works better than an existing immunotherapy drug () for treating advanced lung cancer. Both drugs help your immune system fight cancer cells. The study will enroll 246 patients and compare how well and how safely each medication works as a first-line treatment.

Standard immunotherapy treatments help some lung cancer patients, but researchers believe this new medication might work even better for certain patients. This trial will find out whether the medication is more effective at slowing cancer growth compared to the current standard treatment.

Do you qualify?

You likely qualify if…

you have advanced or metastatic non-small cell lung cancer that cannot be treated with surgery or radiation alone
your cancer has a specific tumor marker (PD-L1 ≥10%) found in a biopsy sample
your cancer does not have certain genetic mutations (EGFR or ALK mutations)
you have not received any previous cancer treatments
you are at least 18 years old and in good enough health to tolerate treatment (ECOG score 0–1)
you have an expected survival of at least 3 months

You likely don't qualify if…

you have specific genetic mutations in your cancer cells (such as ROS1, BRAF, NTRK, MET, or RET mutations)
you have had previous immunotherapy, anti-angiogenic therapy, or certain targeted cancer drugs
you have active brain metastases or multiple brain tumors
you have uncontrolled high blood pressure, diabetes, heart disease, or recent blood clots or stroke within 6 months
you have an active autoimmune disease or history of autoimmune disease

What participation looks like

You would receive either or as an intravenous infusion (injection into a vein) on the first day of every 3-week cycle. The study is double-blind, meaning neither you nor your doctors will know which medication you're receiving—both are given the same way. You'll have regular clinic visits for monitoring, blood tests, and imaging scans to track how your cancer is responding to treatment.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai Chest Hospital, Shanghai, Shanghai Municipality